Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans.

What Was Tested

This randomized controlled trial looks at Nifedipine.

++Endothelin (ET-1) acts as a potent vasoconstrictor in the human kidney, and this vasoconstriction could contribute to the ischemia seen in acute renal failure.

In animal studies, the vasoactive properties of ET-1 are known to be ET(A) receptor-and/or ET(B) receptor-mediated; however, the receptor subtype involved in the human kidney remains to be defined.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Nifedipine and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Nifedipine.

A placebo (an inactive look-alike) gave the Nifedipine group a baseline to be compared against.

Each person switched between Nifedipine and the comparison at some point, usually with a gap in between.

In a phase I, single-center, double-blind, randomized, three-period, crossover design, the effects of orally administered ABT-627, a selective ET(A) receptor antagonist, on renal hemodynamics during ET-1 infusion were evaluated.

What Was Measured

A para-aminohippuric acid/inulin clearance test was performed once at the end of each 7-d treatment period.

The subject headings attached to it are Atrasentan, Calcium Channel Blockers, Diuresis, Endothelin Receptor Antagonists, Endothelin-1, Hemodynamics and Kidney.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Nifedipine.

The publication is from 2000 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: all human trials.